Feature Article

Managing Infection Risk in Psoriasis: Expert Q&A


More research is needed to better understand the pathophysiologic mechanisms that result in increased risk for infection among individuals with psoriasis.

The relative risk for healthcare-associated infections has decreased in the last 15 years due to improvements in awareness of risk associated with devices, infection control, and evidence-based practice regarding use of devices.

Latest News


Secukinumab Superior to Placebo for Treatment of Moderate to Severe Nail Psoriasis

By December 14, 2018

The ability of secukinumab vs placebo to clear nail psoriasis was evaluated using the Nail Psoriasis Severity Index.


Clinical Response Evaluated After Withdrawal, Retreatment With Ixekizumab in Plaque Psoriasis

By December 13, 2018

Investigators evaluated the effect of ixekizumab withdrawal and retreatment in Japanese patients with plaque psoriasis in this single-arm open-label phase 3 study.


New Psoriatic Arthritis Guidelines Recommend TNFi as First-Line Tx Option

By December 12, 2018

The guideline is jointly authored by the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).


Psoriasis Significantly Associated With Inflammatory Bowel Disease

By December 12, 2018

People with psoriasis may have an increased risk for inflammatory bowel disease. Gastroenterology consultation may be indicated when patients with psoriasis present with bowel symptoms.


Ixekizumab Deemed Safe, Effective for Plaque Psoriasis in Real-World Study

By December 11, 2018

Similar to randomized clinical trials, real-life study complements safety and efficacy profiles of ixekizumab treatment in patients with plaque psoriasis.


Psoriasis Linked With Higher Risk for Sexual Dysfunction

By December 10, 2018

People with psoriasis have physical and psychological comorbidities that are associated with a higher risk for sexual dysfunction.


Effectiveness of Online vs In-Person Care for Adult Patients With Psoriasis

By December 06, 2018

Investigators examined whether patients benefited from interacting with their dermatologist online rather than in person to manage their psoriasis.


Clinical Outcomes in Patients With Early-Onset vs Late-Onset Psoriasis

By December 06, 2018

Investigators examined patients with late-onset psoriasis who were treated with etanercept, infliximab, or methotrexate to see whether they were significantly more likely than patients with early-onset psoriasis to have a therapeutic response.


Illuvinate System Now Available for Plaque Psoriasis Treatment

By December 05, 2018

The treatment is based on the Goeckerman regimen which dates back to the 1920s and involves applying coal tar to a patient's skin and exposing the skin to ultraviolet light.


Etanercept May Be Effective in Plaque Psoriasis With Failed Apremilast Therapy

By November 30, 2018

In patients with moderate to severe plaque psoriasis, who have failed to respond to apremilast therapy, etanercept may represent an effective therapeutic option.

Sign up for Newsletters